Authors

Experts discuss the use of biologic treatment in asthma by primary care physicians vs pulmonology specialists as well as overcoming barriers to biologic use through patient and physician education.

Closing thoughts regarding a discussion on improving the management of patients with treatment-resistant depression using newer treatment approaches in a more standardized fashion.

Schultz discussed the SCtalk trial and its findings at ASH 2024.

Panelists discuss how selecting a biologic for atopic dermatitis involves comprehensive assessment of patient-specific factors including age (with dupilumab's broader approval for patients as young as 6 months vs other biologics approved only for those aged 12 years or older), weight (affecting dosing considerations), disease phenotype, symptom predominance (especially itch severity for nemolizumab consideration), comorbidities (including asthma, food allergies, and ocular conditions), prior treatment responses, insurance coverage, administration preferences, anticipated adherence, treatment goals, and previous biologic experience—with biologic-naive patients typically receiving broader consideration, whereas those with prior biologic exposure require careful evaluation of previous response patterns, reasons for discontinuation, and strategic selection of agents with different mechanisms to potentially overcome therapeutic plateaus.

Experts discuss the challenges of identifying and diagnosing hypercortisolism, the reasons behind its often-delayed diagnosis, the impact of a wide spectrum of clinical signs and symptoms on clinicians’ ability to diagnose the condition, and recent data on the prevalence of hypercortisolism in at-risk populations, including those with difficult-to-control diabetes, hypertension, and cardiovascular disease.

The panel of experts offers expert insights and concluding thoughts on the management of primary biliary cholangitis (PBC), emphasizing the importance of personalized treatment strategies, monitoring, and the evolving role of new therapies in improving patient outcomes.

Panelists discuss how differentiating between wild-type transthyretin amyloid cardiomyopathy (wATTR-CM) and hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is essential for accurate diagnosis, tailored treatment strategies, and better management of patient outcomes, given their distinct pathophysiologies, disease progression, and treatment options.

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, and Madeline King, PharmD, BCIDP, provide insight on vaccine hesitancy among patients and the importance of increasing vaccine uptake to protect against SARS-CoV-2.

Dr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.

Overall, Asthma Control Test (ACT) measures improved by 37%.